By Michael Erman

NEW YORK (Reuters) -Pfizer Chief Executive Albert Bourla said on Tuesday that the U.S. pharmaceutical industry needs to collaborate with China’s, where speedy processes have vaulted it to 30% of global drug development over the past decade.

“In biopharma, China’s dramatic speed, cost and scale have triggered a shift in the global competitive landscape,” Bourla said, speaking at the National Committee on U.S.-China Relations Gala in New York.

He said the country currently has around 1,200 novel drug candidates, compared with 10 years ago when there was about 60.

The remarks come as U.S. President Donald Trump has targeted top economic rival China with a cascade of tariff orders on billions of dollars of imported goods that he says is aimed at narrowing a wide trade defi

See Full Page